Overview of Sultam

Sultam is a general pharmaceutical name for a medicine defined by its active component, Sulbactam, which is classified as a specialized anti-infective agent. Its primary role is to serve as an enhancer in antibiotic therapy by defeating bacterial defenses.

Property	Description
Active ingredient	Sulbactam
Form	Powder for solution for injection; Tablets
Pharmacological class	beta-Lactamase Inhibitor
Common use	Defeating bacterial resistance to antibiotics
Origin	Semisynthetic

Sultam: Definition and Pharmacological Classification

Sultam is based on the active ingredient Sulbactam, which belongs to the distinct pharmacological class of beta-Lactamase Inhibitors. This medication is a semisynthetic compound, chemically derived from the core structure of penicillin, placing it within the broader group of antibacterials. The classification as a beta-lactamase inhibitor separates it from direct antibacterial agents, underscoring its function as a supportive medication crucial for effective infection management. Sulbactam is classified as an antibacterial agent for systemic use. This means the medicine is designed to work throughout the body to fight bacterial issues, a mechanism clinically recognized for its value in managing complex microbial threats.

Composition and Common Pharmaceutical Forms

Sulbactam is almost always formulated as a combination product, pairing the inhibitor with a co-active beta-lactam antibiotic, such as Ampicillin, to create a fixed-dose drug. This composition is predominantly supplied as a sterile Powder for solution for injection, intended for the parenteral route. This characteristic is a key differentiating factor, often signaling its use in settings requiring rapid action. The combination approach ensures that both the enzyme inhibitor and the antibiotic are delivered simultaneously. beta-lactamase inhibitors play an essential role in combination products to extend the therapeutic life of conventional antibiotics.

General Purpose: Overcoming Antibiotic Resistance

The general purpose of Sulbactam is to defeat bacterial resistance to standard antibiotics, ensuring their continued effectiveness in treating infections. It functions by neutralizing the protective bacterial enzymes, called beta-lactamases, which would otherwise break down and inactivate the co-administered partner antibiotic. This key action restores the power of the primary antibacterial agent, effectively expanding the range of infections that the combination therapy can successfully manage. A typical, neutral use scenario involves its application when infections are suspected to be caused by beta-lactamase-producing organisms.

Regulatory References

NIH Review

What side effects are possible with Sultam?

The safety profile of Sultam (Sulbactam) is documented primarily through its use in combination with a partner antibiotic, with adverse reactions formally classified by regulatory authorities.

Frequency-Classified Adverse Reactions

Side effects are categorized based on incidence rates found in official regulatory labeling. Most Common effects (occurring in greater than 10% in some contexts) include gastrointestinal issues like diarrhea, and laboratory changes such as anemia, hypokalemia, and elevated liver test abnormalities (AST/ALT). Common effects (1% to 10%) typically involve rash and localized injection site reactions.

Serious Adverse Reactions and Safety Constraints

Official prescribing information highlights several serious adverse reactions. These include potentially fatal anaphylactic reactions and severe, life-threatening skin disorders such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Like other antibacterial agents, use may lead to severe Clostridioides difficile-associated diarrhea (CDAD), which can manifest even months after treatment cessation. Neurological effects, specifically convulsions, have been noted, particularly in overdose or high exposure.

Contraindications established in regulatory documents prohibit use in individuals with a history of serious allergic reactions to Sultam or other related beta-lactam antibacterial drugs (e.g., penicillins).

Population-Specific Safety Notes

The medicine's safety documentation includes specific considerations for patients with altered drug elimination. Those with impaired renal function exhibit a significantly longer half-life for Sulbactam. Caution is also advised when treating neonates due to their immature urinary systems and in patients with a history of aminopenicillin-induced hepatitis.

Overdose and Emergency Response

The official regulatory profile for Sultam (Sulbactam) overdose focuses on severe potential outcomes and mandated procedural management. Official prescribing information often indicates that no specific information is available regarding the precise clinical signs or symptoms associated with an acute overdose of this medication.

The most serious documented manifestation is the potential for neurological adverse reactions, specifically convulsions (seizures). This outcome is associated with the attainment of high concentrations of beta-lactam derivatives, a class including Sulbactam, in the Cerebrospinal Fluid (CSF). The occurrence of convulsions represents a state requiring immediate and urgent medical evaluation.

Treatment is mandated by regulators to be symptomatic and supportive, reflecting the fact that no specific antidote is known. For severe cases, regulatory labeling states that Sulbactam is considered removable by hemodialysis. However, it is an important regulatory caveat that clinical information is limited concerning the use of hemodialysis specifically for managing overdosage.

A critical population-specific note is documented for patients with impaired renal function. Because the drug is primarily cleared by the kidneys, reduced function can lead to elevated and prolonged systemic exposure, thereby increasing the risk of overdose effects.

Therapeutic Uses of Sultam

Quick Facts: Uses of Sultam (as a combination therapy component)

Therapeutic Domain: Managing bacterial infections in multiple body areas.
Target Infections: Addresses infections of the skin and skin structure, intra-abdominal infections, and gynecological infections.
Action: Used in combination with a partner antibiotic to help restore its activity against resistant bacteria.

Sultam, typically administered as a combination product (e.g., with ampicillin or cefoperazone), is employed in the therapeutic management of infections caused by certain susceptible bacteria. The addition of Sultam helps prevent bacterial enzymes from degrading the companion antibiotic, thereby helping to broaden the scope of antimicrobial activity.

This medication is indicated for specific infections, which may include those affecting the skin and soft tissues, conditions within the abdominal cavity, and gynecological infections, such as pelvic inflammatory disease. In a newer combination, a Sultam derivative is used in the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by certain resistant organisms.

Regulatory References

NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Sultam — official regulatory information

The eligibility profile for Sulbactam (Sultam) is defined by governmental regulatory authorities based on patient history, age, and physiological status.

Eligibility Scope
Populations for whom use is contraindicated: Individuals with a history of serious hypersensitivity reactions to Sulbactam, Ampicillin, or any other beta-lactam antibacterial drug. Use is also contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with ampicillin-class drugs.
Populations for whom use is allowed (as stated in label): Use is established in adults (typically 18 years of age) and generally in pediatric patients one year of age and older for approved indications.
Age-related eligibility rules: Neonates and premature infants are subject to special caution due to their underdeveloped urinary systems. Older adults are typically treated based on an assessment of their renal function.
Condition-specific eligibility rules: Use is restricted in patients with severe renal impairment; official labeling requires a modification to the administration regimen to account for reduced drug clearance. Monitoring is also required for patients with pre-existing hepatic impairment.
Pregnancy and lactation eligibility status: Use during pregnancy is generally permitted only if clearly needed, based on official regulatory classification. Sulbactam is excreted into human milk, and use during lactation is generally considered acceptable.

Eligibility Classifications (High-Level)

Regulatory Basis	Eligibility Severity Classification
FDA Prescribing Information, EMA SmPC	Absolute Contraindication (Hypersensitivity, Hepatic History); Restricted/Conditional Use (Renal Impairment, Neonates).

Official regulatory documents define the eligible population by excluding individuals with established beta-lactam allergies or a history of drug-induced liver injury. Use in populations with impaired renal function is conditional, as their reduced ability to clear the drug requires strict management, a restriction formalized in government labeling.

What should I know about interactions with other medicines?

Sultam Interactions with Other Medicines and Products

The interaction profile for Sultam, typically formulated as Sulbactam in combination with a beta-lactam antibiotic, is defined by regulatory documents focusing on pharmacokinetic and pharmacodynamic outcomes.

Documented Interaction Patterns

Interaction Type	Interacting Substance	Official Regulatory Outcome
Pharmacokinetic (Reduced Clearance)	Probenecid	Decreases renal tubular secretion, resulting in increased and prolonged plasma concentrations of Sulbactam and the partner antibiotic.
Pharmacodynamic (Potentiation)	Anticoagulants	Reported to increase the anticoagulant effect, potentially leading to a prolonged Prothrombin Time (PT).
Pharmacodynamic (Antagonism)	Bacteriostatic Agents	May interfere with the bactericidal action of the partner antibiotic; concurrent use is cautioned against by regulators.
Pharmacodynamic (Hypersensitivity Risk)	Allopurinol	Concomitant use with the Ampicillin component is associated with a significantly increased incidence of skin rash.

Restrictions and Procedural Constraints

No specific medicinal product is universally designated as contraindicated with Sulbactam itself. However, the regulatory documentation requires monitoring for patients co-administered with anticoagulants. Furthermore, the medicine is documented to interfere with certain laboratory tests by causing a false-positive reaction in urine glucose tests that utilize cupric sulfate solutions. No specific interactions with food, alcohol, or common supplements are detailed in the major regulatory labeling.

Mechanism of Action

Targeting Enzymes with Irreversible Covalent Blockade

Sultam functions as an irreversible covalent inhibitor, meaning it physically and permanently blocks the function of specific target enzymes by forming a chemical bond with their active sites. This action is mediated by the molecule's reactive core, which undergoes sulfonylation to inactivate the key serine residue within the enzyme's catalytic pocket. This mechanism results in the sustained inactivation of target enzymatic activity, thereby modulating the affected biochemical process.

Modulating Key Biological Signaling Cascades

By inactivating its specific enzyme target, Sultam effectively interrupts the entire sequence of downstream events, or signaling cascade, reliant on that enzyme's function. This results in an altered signaling output from pathways characterized by increased activity. If Sultam is combined with another active compound, its mechanism often includes acting as a chemical decoy to irreversibly neutralize destructive enzymes that would otherwise break down its partner drug. This protective action maintains a higher concentration of the partner drug at the target site, supporting its specific mechanistic action.

Dosage and Administration Information

How Sultam is Used: Official Administration Guidelines

Sultam (Sulbactam) is a beta-Lactamase Inhibitor that is officially administered only as a component of fixed-ratio combination products (e.g., Ampicillin/Sulbactam or Sulbactam/Durlobactam). The administration instructions are precise and non-interchangeable with other forms.

Administration Scope

Instruction Entity	Regulatory Standard
Route of Administration	Intravenous (IV) infusion/injection or Intramuscular (IM) injection only.
Adult Dosing Schedule	The standard adult dose for the Ampicillin/Sulbactam combination is 1.5 g to 3 g (total drug content) per administration, typically given at intervals of every 6 hours (q6h).
Maximum Dose	The maximum recommended daily dose for the Sulbactam component in adults is 4 grams.

Preparation and Special Conditions

The medication is supplied as a sterile powder for solution for injection and must be correctly prepared before use.

Preparation Requirement: The powder must be reconstituted with a specific volume of Sterile Water for Injection or other compatible diluent and then further diluted prior to IV infusion.
Infusion Time: Administration time is strictly controlled: Ampicillin/Sulbactam is given over 10–30 minutes, while Sulbactam/Durlobactam is administered as a 3-hour IV infusion.
Course Duration: The recommended duration of treatment is typically 7 to 14 days, guided by the clinical status of the patient.

Population-Specific Adjustments

Dosage regimens must be adjusted in specific patient groups to account for the clearance of the Sulbactam component, which is primarily renal.

Renal Impairment: For patients with reduced kidney function (e.g., creatinine clearance < 30 mL/min), the dosing interval must be extended (e.g., from q6h to q12h or q24h) while maintaining the standard individual dose.
Pediatric Use: Dosing is determined by body weight, and the maximum daily Sulbactam component dose must not exceed 80 mg/kg/day.

This collection of instructions dictates the required procedural steps and frequency modifications necessary for the drug's official and standardized administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sultam

1. Evidence for Use in Common Bacterial Infections

Research explores the use of Sulbactam (Sultam) in combination with other antibiotics in contexts involving bacterial infections in common areas of the body. These studies, often comparative trials, provide context regarding the patterns observed across the studied populations.

Clinical trials have been used in research exploring how the symptoms of complicated skin and skin structure infections change over defined time intervals. These studies typically involved hospitalized adults and, in some cases, pediatric patients. Researchers tracked outcomes related to physical discomfort and systemic or functional imbalance by measuring the clinical cure rate (a predefined endpoint in the trial protocol) and the clinical response rate (a measurement of change in the patient's status).

Sultam combination therapy was evaluated in randomized controlled trials and observational settings in contexts associated with acute or disruptive episodes, such as intra-abdominal infections and gynecological infections (including pelvic inflammatory disease). Findings describe patterns observed in these studies, with trials reporting measurements of the predefined primary endpoints across the patient cohorts. Evidence contributes to understanding symptom patterns, but much of the data comes from older trials, and comparative evidence is lacking against the newest available treatments.

2. Evidence for Use in Highly Resistant Infections

Research also extends to contexts involving bacteria that have developed resistance to multiple antibiotics. Studies in these areas are often newer and focus on outcomes in critical care settings. The use of newer Sultam derivatives in combination was evaluated in Phase 3 Randomized Controlled Trials (RCTs) specifically for critically ill adults in contexts such as Hospital-Acquired Pneumonia (HAP) or Ventilator-Associated Pneumonia (VAP) caused by certain resistant organisms.

In these studies, a key outcome tracked was 28-day All-Cause Mortality, alongside the clinical cure observed at a set follow-up visit. However, results apply only to the specific, limited populations studied, and the evidence quality varies across studies, with data describing patterns primarily in studies involving newer, specific Sulbactam derivative combinations.

3. What Is Still Uncertain About Sultam Research

The majority of research exploring Sultam combination therapy is short-term. The primary limitation across much of the evidence is the short follow-up duration, which leaves long-term outcomes and the risk of infection recurrence not well characterized. Furthermore, comparative evidence is lacking in some areas against the newest generation of antibiotics. For the most resistant infections, the evidence quality varies across studies, with certainty remaining low due to the reliance on retrospective data and small sample sizes. Research does not determine whether an individual will respond similarly to the group patterns observed in studies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Sultam (FAQ)

Q: What is the main reason doctors prescribe Sultam?

A: The general purpose of Sultam is related to its role as an enhancer in combination therapy. It is used to defeat bacterial resistance, supporting the effectiveness of the primary antibiotic partner in managing infection.

This action helps restore the power of the co-administered antibacterial agent to manage infections that might be resistant to standard treatments.

Q: What are the most common things Sultam is used for?

A: According to official regulatory information, Sultam-containing combination products are indicated for treating certain infections caused by specific susceptible bacteria. This includes infections in areas such as the abdomen, the pelvis, and the lungs.

The medicine is used to manage these conditions where the bacteria may be resistant to other antibiotics.

Q: What conditions are listed in the official FDA label for Sultam?

A: Official FDA labeling indicates Sultam-containing combinations are used to treat infections like Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia caused by specific susceptible organisms.

These indications apply only when the infection is confirmed or suspected to be caused by specific organisms, as defined by the prescribing information.

Q: What does 'contraindication' mean in the context of Sultam?

A: A contraindication is an official term used in regulatory documents to describe a condition or factor that prohibits the use of a medicine because the potential risk of harm is considered greater than any benefit.

In the context of Sultam, an absolute contraindication is having a known history of a severe allergic reaction to the medicine itself or to related antibiotics.

Q: What is the definition of a 'serious' adverse reaction to Sultam?

A: A serious adverse reaction is a classification used by regulatory bodies for an unwanted effect that results in death, is life-threatening, or requires hospitalization.

Official labeling uses this classification to highlight potential events such as severe allergic reactions (anaphylaxis) or severe skin disorders, which may represent a medical emergency.

Q: Are there any common over-the-counter medicines that interact with Sultam?

A: Official regulatory documentation does not detail specific interactions with common non-prescription, over-the-counter medicines.

Reference to the full interaction profile is part of understanding the medication's use, especially regarding certain prescription substances that are listed.

Q: Is it normal to feel a mild stomach upset when starting Sultam?

A: Gastrointestinal issues, including diarrhea and reports of nausea or vomiting, are among the effects classified as common or most common in regulatory documentation.

These types of effects are noted in the official adverse reaction list, indicating they are known outcomes observed in some patients.

Q: What are the signs of a serious side effect from Sultam?

A: Serious adverse reactions described in official labeling may include signs related to severe allergies, such as swelling of the face, hives, or difficulty breathing. They also cover severe skin disorders, which might present as blistering or peeling skin.

These events are regarded as potential medical emergencies.

Q: How long does Sultam stay in your system after you stop taking it?

A: The drug's components are typically excreted via the urine.

In people with normal kidney function, most of the components are usually cleared from the body within about 8 hours after administration. Elimination is prolonged in individuals with reduced kidney function.

Q: Can women who are planning pregnancy use Sultam?

A: Official regulatory documents generally state that the use of Sultam during pregnancy is permitted only when clearly needed.

The official labeling does not provide specific guidance regarding the pre-conception period or the planning stage, and is therefore addressed within the context of individual patient care.

Q: Does Sultam affect blood sugar levels?

A: Regulatory information notes that Sultam has been documented to interfere with certain urine glucose tests that use cupric sulfate solutions, which can cause a false-positive result in the test.

This interference relates to the lab test itself, rather than a direct physiological effect on blood sugar levels in the body.

Q: Is Sultam known to cause fatigue or drowsiness?

A: While not classified as a common side effect in all labels, regulatory data notes that unusual tiredness or weakness has been observed and reported as an adverse reaction in some patients.

This observation is documented in official safety information.

Q: Why do some people say they feel 'fuzzy' after taking Sultam?

A: Official documents note the potential for Central Nervous System (CNS) effects as part of the safety profile.

These CNS effects have included convulsions, especially in patients with reduced kidney function or high exposure to the medicine.

Q: Can Sultam affect my sleep schedule?

A: Adverse reaction reporting includes some central nervous system effects such as agitation, confusion, and irritability.

These are effects that may generally impact a person’s level of alertness and subsequently affect the quality or pattern of sleep.

Q: Is Sultam a type of controlled substance?

A: Sultam (Sulbactam) or its common combination products are not classified as controlled substances by federal regulatory bodies.

This classification is used for drugs that have accepted medical uses but also have a potential for dependence or abuse.

Q: Does Sultam have a weight gain or weight loss side effect?

A: Although not listed as a common side effect, some regulatory documents mention reports of rapid weight gain or unusual weight loss as adverse reactions with incidence not specifically known.

These are reported outcomes observed during clinical surveillance.

Q: Is Sultam safe for people with a history of heart issues?

A: Official safety documents report arrhythmia (irregular heartbeat) as an adverse reaction observed in clinical trials, indicating potential cardiac effects.

The documented reports of arrhythmia are part of the information used by prescribing professionals when assessing patient risk.

Q: Are headaches a commonly reported side effect of Sultam?

A: Headache is listed as one of the commonly reported adverse reactions in clinical trial data for some Sulbactam combination products.

Official labeling indicates these effects occurred in ge 3% of patients in specific study contexts.

How should Sultam be stored and disposed of?

How to Store and Dispose of Sulbactam

Official regulatory labeling dictates strict conditions for the storage and disposal of Sulbactam, which vary between the dry powder and the prepared solution.

Storage Requirements

Condition	Powder (Unreconstituted)	Solution (Prepared for Infusion)
Temperature	Controlled Room Temperature (20 C to 25 C)	Use within 24 hours at room temp. or up to 4 days refrigerated (2 C to 8 C)
Protection	Store in the original container to protect from light and moisture.	Do not freeze the prepared solution.

Handling and Disposal

The medicine must be kept out of the sight and reach of children. After preparation, the solution for infusion must be used within the specific time limits defined by the product label. Any unused portions or expired product must be discarded in accordance with all applicable federal, state, and local regulations. Disposal into wastewater is not recommended.

Sultam